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NO T E S AND COMMEN T S
Pitfall regarding expression of ETS-related gene (ERG) in
fibrohistiocytic neoplasms
I read with great interest the recent paper entitled “EWSR1-SMAD3
rearranged fibroblastic tumor: Case series and review,” which is the
largest case series to date reviewing the histopathological features
of this newly described entity.1 Dermatopathologists should wel-
come this contribution given the common occurrence of spindled
cell tumors that are difficult to precisely classify in clinical practice.
Furthermore, the authors provide a nice overview of the differential
diagnosis for this tumor in Table 2 and cite two other papers dis-
cussing potential mimickers.2,3
I find it interesting that none of the groups that have published
on EWSR1-SMAD3 rearranged fibroblastic tumor (ESFT) have included
cellular fibrous histiocytoma in the differential diagnosis. Certainly,
there appear to be morphological/architectural features which may in
some circumstances assist in discriminating the two (notably the zona-
tion with foci of hyalinization) on a complete excision. However, many
of the biopsy specimens that dermatopathologists receive are
superficial samples and the presence of spindled cells in hypercellular,
well-organized, and intersecting fascicles can be seen in cellular
fibrous histiocytoma. Moreover, fibrous histiocytoma can arise on
acral surfaces, is easily the most commonly biopsied fibrous tumor of
the skin, and may not reliably stain for commonly used fibrohistiocytic
markers on immunohistochemistry.
The authors emphasize that ETS-related gene (ERG) is uniformly
expressed in ESFT in contrast to many of the other entities on the dif-
ferential diagnosis. There is a paucity of literature regarding ERG
expression in fibrohistiocytic proliferations in general, though we
recently encountered an acral cellular fibrous histiocytoma at our
institution that demonstrated strong and diffuse staining for ERG
(Figure 1). Moreover, given the lack of expression of other commonly
used markers in this setting (Fac13a, CD34, SMA, CD163, CD68) a
next-generation sequencing panel was ordered, which failed to detect
the EWSR1-SMAD3 translocation. There is one published abstract
F IGURE 1 Top panel demonstrates a
dermal-based proliferation of spindled cells
in fascicles pressed up against the
epidermis with peripheral collagen trapping
(hematoxylin and eosin [H&E], ×40, original
magnification). Lower right panel shows
relatively monomorphous plump spindled
cells in hypercellular fascicles (H&E, ×200,
original magnification). Lower left panel
shows intense expression of ERG (H&E,
×200, original magnification)
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which reported consistent expression of ERG in fibrous histiocytoma
and giant cell tumor of the tendon sheath.4 Moreover, it is well
established that some case of epithelioid sarcoma express ERG.5 If
additional neoplasms of fibrohistiocytic origin are found to express
ERG, it would become a much less helpful adjunct in this setting. This
would be important to establish to mitigate the use of costly sequenc-
ing panels.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were cre-
ated or analyzed in this study.
Ben J. Friedman MD1,2
1Department of Dermatology, Henry Ford Health System, Detroit,
Michigan
2Department of Pathology and Laboratory Medicine, Henry Ford Health
System, Detroit, Michigan
Correspondence
Ben J. Friedman, MD, Department of Dermatology, Henry Ford




Ben J. Friedman https://orcid.org/0000-0002-2266-8197
REFERENCES
1. Habeeb O, Korty KE, Azzato EM, et al. EWSR1-SMAD3 rearranged fibro-
blastic tumor: case series and review. J Cutan Pathol. 2021;48(2):255-262.
2. Kao YC, Flucke U, Eijkelenboom A, et al. Novel EWSR1-SMAD3 gene
fusions in a group of acral fibroblastic spindle cell neoplasms. Am J Surg
Pathol. 2018;42(4):522-528.
3. Michal M, Berry RS, Rubin BP, et al. EWSR1-SMAD3-rearranged fibro-
blastic tumor: an emerging entity in an increasingly more complex
group of fibroblastic/myofibroblastic neoplasms. Am J Surg Pathol.
2018;42(10):1325-1333.
4. Beshai B, Cartun R, Mandavilli S. ERG immunohistochemical (IHC)
expression in fibrohistiocytic tumors: a diagnostic pitfall. Am J of Clin
Pathol. 2015;144(2,1):A309.
5. Miettinen M, Wang Z, Sarlomo-Rikala M, Abdullaev Z, Pack SD,
Fetsch JF. ERG expression in epithelioid sarcoma: a diagnostic pitfall.
Am J Surg Pathol. 2013;37(10):1580-1585.
How to cite this article: Friedman BJ. Pitfall regarding
expression of ETS-related gene (ERG) in fibrohistiocytic
neoplasms. J Cutan Pathol. 2021;1–2. https://doi.org/10.
1111/cup.14024
2 FRIEDMAN
